Blood Flow Restriction for Sclerosis
Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis
See full descriptionAbout the trial for Sclerosis
Treatment Groups
This trial involves 2 different treatments. Blood Flow Restriction is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for female patients between 18 and 65 years old. There are 5 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Blood Flow Restriction will improve 5 primary outcomes and 1 secondary outcome in patients with Sclerosis. Measurement will happen over the course of Day 2, Week 4 and 8, Day 28.
Patient Q & A Section
What is sclerosis?
A few key characteristics of sclerosis should be considered. In the beginning, symptoms are similar to those found in any chronic condition where blood clot formation is abnormal. In the late stages of the disease, the formation of blood clots is not a main problem, though clot formation can persist. Patients will notice the first noticeable symptom in the beginning of their fifties. Although symptoms can be controlled for some time, recovery from the debilitating symptoms of a sclerosis related illness is a rare phenomenon. However, once symptoms have been controlled, patients can often live a normal life.
What are common treatments for sclerosis?
Arterial stiffness is common both within and among different ethnic groups and can be reduced and/or controlled through pharmacology, exercise and lifestyle modifications. These can benefit the majority of patients with arterial sclerosis.
How many people get sclerosis a year in the United States?
There is little agreement on rates of scleroderma among American rheumatologists. There is great variability in the numbers of Medicare and private claims from different clinical practices.
What causes sclerosis?
There is no single cause of scleroderma: there are triggers causing scleroderma to develop, and autoimmune, genetic and hormonal factors that affect scleroderma’s development. Scleroderma can also develop after long periods of not having symptoms, with various other conditions raising the risk for scleroderma, often in combination.\n
What are the signs of sclerosis?
sclerosis is an age-related disorder that leads to loss of joint function, joint space narrowing, decreased range of movement, osteoarthritis, and osteoporosis. Sclerosis is more common in females and presents most commonly with knee osteoarthritis with increased pain. This disease does not always lead to deformity and amputations. Sclerosis patients may be symptomatic, but will have no deformity and will not require surgery.
Have there been any new discoveries for treating sclerosis?
The current therapies to treat sclerosis including steroids in steroid-responsive SSc and intravenous immune globulin in SSc have been proven satisfactory and have not been replaced by any other treatments.
What is the primary cause of sclerosis?
There are multiple diseases that cause sclerosis: they are not the primary cause of this disease. The primary cause is unknown but likely involves genetics, the environment, inflammation and viral infections.
Have there been other clinical trials involving blood flow restriction?
There was a significant reduction in blood flow to the affected area after 10-minutes of treatment. This decrease was related to a significant decrease in heart rate and oxygen saturation as well as an increase in blood flow velocity in the area. Patients also reported that they found the exercise painful. Although blood flow restriction is a very new treatment for heart disease, further prospective research and trials are needed to establish its use as a cardiovascular medicine.
How does blood flow restriction work?
The application of BF is not a useful tool for peripheral artery remodelling. Although it has been demonstrated that BF is able to reduce vascular remodelling, blood flow redistribution could be an alternative mechanism. Although this has not been studied directly, it could explain the inconsistent results that have been obtained with BF application to the extremities.
What is the latest research for sclerosis?
Scler sclerosis is the most common presentation of chronic liver disease. Although the liver is affected in over 75% of patients with scleroderma and only 15% of patients with [primary biliary cirrhosis](https://www.withpower.com/clinical-trials/primary-biliary-cirrhosis) it seems that only a minority of patients will develop liver cirrhosis. There is some evidence that statin use may reduce the risk of developing severe liver problems. Liver transplantation is the standard treatment for those with end stage liver disease. The new class of immunosuppressant drugs has expanded the potential options for patients with scleroderma and have significantly improved patients' functional status.
What does blood flow restriction usually treat?
These data are consistent with the hypothesis that decreased tissue oxygenation and metabolic fluxes from blood to tissues plays a role in the treatment of various musculoskeletal conditions. These observations are in agreement with previous animal and human data and warrant further evaluation of blood flow restriction as the new paradigm in the management of musculoskeletal pain.